Participants 394 549 5
70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m2 subcutaneously three times a week).
Participants 556 631 5
63 evaluable patients, similar response rates (62.1% and 64.7% respectively
